MNBTD
TBPH

Moody National Bank Trust Division’s Theravance Biopharma TBPH Stock Holding History

Moody National Bank Trust Division’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-250
Closed -$6K – 907
2019
Q1 		$6K Buy
+250
New +$6.34K ﹤0.01% 810

Other funds holding TBPH

WIM
Woodford Investment Management London, United Kingdom $310M AUM 17.41% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Moody National Bank Trust Division's TBPH Position: Q2 2019 in Review

Moody National Bank Trust Division sold out of Theravance Biopharma (TBPH) in Q2 2019, closing a stake of 250 shares — an estimated $6K sold.

Moody National Bank Trust Division first reported a position in TBPH in Q1 2019 and held it in 1 quarter. The position peaked at $6K in Q1 2019. 98 funds tracked by Wall St. Rank hold TBPH as of Q2 2019.

  • Moody National Bank Trust Division reported no remaining Theravance Biopharma position as of Q2 2019 after selling out during the quarter.
  • Moody National Bank Trust Division sold 250 Theravance Biopharma shares in Q2 2019, an estimated $6K.
  • Moody National Bank Trust Division first reported a position in Theravance Biopharma in Q1 2019 and held it in 1 quarter.
  • Moody National Bank Trust Division's Theravance Biopharma position peaked at $6K in Q1 2019.
  • 98 funds tracked by Wall St. Rank held Theravance Biopharma as of Q2 2019.

Based on Moody National Bank Trust Division's 13F filing for Q2 2019, filed 22 Jul 2019.